Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Halozyme and Vertex sign deal for Hypercon technology

 April 8, 2026

Pharmaceutical Business Review

Vertex has licensed the technology for use in up to three drug targets, as part of the agreement.

M&A / DealsRead full story

Post navigation

Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis →
← RoosterBio and MineBio team up to expand MSC solutions access in China

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com